10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2017 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 8, 2018) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Cash flows from operating activities: | |||
| Net income | $ 1,198,511 | 895,522 | 636,056 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 145,467 | 104,745 | 74,909 |
| Non-cash compensation expense | 507,277 | 559,878 | 459,049 |
| Other non-cash charges and expenses, net | 63,581 | 45,139 | 52,562 |
| Deferred Taxes | 318,809 | (360,078) | (121,623) |
| Changes in assets and liabilites | |||
| Increase in Sanofi, Bayer, and trade accounts receivable | (362,720) | (143,827) | (491,421) |
| Increase in Inventories | (314,195) | (149,776) | (111,825) |
| (Increase) decrease in prepaid expenses and other assets | (113,331) | 23,543 | (79,476) |
| (Decrease) increase in deferred revenue | (113,099) | 244,270 | 608,892 |
| (Decrease) increase in accounts payable, accrued expenses and other liabilities | (23,188) | 253,980 | 303,657 |
| Total adjustments | 108,601 | 577,874 | 694,724 |
| Net cash provided by operating activities | 1,307,112 | 1,473,396 | 1,330,780 |
| Cash flows from investing activities: | |||
| Purchases of marketable and other securities | (1,277,140) | (809,419) | (557,105) |
| Sales or maturities of marketable securities | 544,584 | 274,456 | 327,437 |
| Capital expenditures | (272,626) | (511,941) | (677,933) |
| Net cash used in investing activities | (1,005,182) | (1,046,904) | (907,601) |
| Cash flows from financing activities: | |||
| Proceeds in connection with capital and facility lease obligations | 57,000 | 5,085 | 27,373 |
| Payments in connection with capital and facility lease obligations | (19,925) | (32,774) | (1,353) |
| Repayments of convertible senior notes | 0 | (12,894) | (166,467) |
| Payments in connection with reduction of outstanding warrants | 0 | (643,365) | (573,487) |
| Proceeds from issuance of Common Stock | 240,213 | 126,739 | 206,358 |
| Payments in connection with Common Stock tendered for employee tax obligations | (301,688) | (143,182) | (160,537) |
| Excess Tax Benefit from Share-based compensation | 0 | 0 | 405,317 |
| Net cash used in financing activities | (24,400) | (700,391) | (262,796) |
| Net increase (decrease) in cash and cash equivalents | 277,530 | (273,899) | 160,383 |
| Cash and cash equivalents at beginning of period | 535,203 | 809,102 | |
| Cash and cash equivalents at end of period | 812,733 | 535,203 | 809,102 |
| Cash paid for interest (net of amounts capitalized) | 18,678 | 5,454 | 10,582 |
| Cash paid for income taxes | 754,843 | 481,360 | 276,092 |
| Class of Warrant or Right | |||
| Warrant | |||
| Payments in connection with reduction of outstanding warrants | (399,500) | ||
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |